Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INB-400
- Development stage
- Discontinued
- Lead developer
- IN8bio
- Modality
- Cell Therapies
- Administration
- Intracranial (via Rickham Catheter)
01
Overview
INB-400 is an autologous gamma-delta T cell therapy product candidate genetically engineered to survive chemotherapy and maintain the natural ability to recognize, engage, and kill cancer cells. It is developed by IN8bio, Inc., and is primarily indicated for the treatment of glioblastoma. The therapy combines engineered, chemotherapy-resistant gamma-delta T cells with standard-of-care treatments to amplify immune signals and maximize tumor killing.
- Other names
- Autologous genetically modified gamma-delta T cellsDeltEx DRI
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on INB-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INB-400.